Johnson & Johnson vaccine paused over rare blood clots
The US, South Africa and European Union have said they are temporarily halting the rollout of the Johnson & Johnson (J&J...
You are offline
Good Health and Well-being
World Health Organization grants emergency use authorization to Johnson & Johnson vaccine
The World Health Organization on Friday granted emergency use authorization to the COVID-19 vaccine developed by Johnson & Johnson JNJ, +0.29% and added it to its Covax program, which aims to ensure vaccine equity for lower income countries. "Every new, safe and effective tool against COVID-19 is another step closer to controlling the pandemic," said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. "But the hope offered by these tools will not materialize unless they are made available to all people in all countries." The J&J vaccine has the advantage over others that it requires just one dose and does not have the same refrigeration requirements as the vaccines developed by Pfizer Inc. PFE, +0.66% and German partner BioNTech SE BNTX, +0.66%, or the one developed by Moderna Inc. MRNA, -2.48%. Those two shots require two doses weeks apart. Johnson & Johnson shares rose 0.3% Friday and are up 27% in the last 12 months.
View SourceRelated Notices
Covid-19: US agencies call for pause in Johnson & Johnson vaccine
US health authorities are calling for a pause in the use of the Johnson & Johnson Covid-19 vaccine, after reports of ext...
World Health Organization reports 10% weekly rise in virus cases
The World Health Organization reported there was a 10 per cent rise in new coronavirus cases globally last week, drive...
This notice has been removed
The content is no longer available
World Health Organization grants emergency use authorization to Johnson & Johnson vaccine
The World Health Organization on Friday granted emergency use authorization to the COVID-19 vaccine developed by Johnson & Johnson JNJ, +0.29% and added it to its Covax program, which aims to ensure vaccine equity for lower income countries. "Every new, safe and effective tool against COVID-19 is another step closer to controlling the pandemic," said WHO Director-General, Dr Tedros Adhanom Ghebreyesus. "But the hope offered by these tools will not materialize unless they are made available to all people in all countries." The J&J vaccine has the advantage over others that it requires just one dose and does not have the same refrigeration requirements as the vaccines developed by Pfizer Inc. PFE, +0.66% and German partner BioNTech SE BNTX, +0.66%, or the one developed by Moderna Inc. MRNA, -2.48%. Those two shots require two doses weeks apart. Johnson & Johnson shares rose 0.3% Friday and are up 27% in the last 12 months.
Recent Searches
Recent Noticeboards
Trending
No results found
Try a different search term
Something went wrong
No notices yet
No notices match these filters
Couldn't load notices
You're all caught up 🎉
Discussion (0)
No comments yet